GSK announced that Risvanzutibart (Ris-Rez), an antibody-drug conjugate (ADC) targeting B7-H3, achieved positive results in a Phase III clinical trial involving patients in China with extensive-stage small cell lung cancer (ES-SCLC) whose disease had progressed after first-line platinum-based chemotherapy.
According to the company, the study met its primary endpoint by demonstrating a statistically significant improvement in overall survival (OS) compared with chemotherapy. Secondary endpoints, including progression-free survival (PFS) and objective response rate (ORR), also favored Ris-Rez.
The trial was conducted by Hansoh Pharma, which originally developed the therapy before licensing global rights outside mainland China, Hong Kong, Macau and Taiwan to GSK. Detailed clinical data are expected to be presented at a future medical meeting and submitted to regulatory authorities.
Why this result matters
Small cell lung cancer remains one of the most aggressive forms of lung cancer, with limited treatment options once patients experience disease progression following first-line therapy. Although advances in immunotherapy have improved outcomes for some patients, effective second-line treatments capable of extending survival remain scarce.
Against this backdrop, the positive Phase III findings represent an important development for both patients and the broader oncology field. According to GSK, Ris-Rez is the first B7-H3-targeting ADC to demonstrate an overall survival benefit in a Phase III trial, marking a significant milestone for this emerging therapeutic class.
The findings also strengthen scientific interest in B7-H3, a target that has attracted increasing attention across the oncology industry due to its broad expression in multiple solid tumors.
GSK continues to expand its ADC portfolio
The latest clinical success supports GSK’s broader strategy of strengthening its oncology pipeline through antibody-drug conjugates.
Rather than relying solely on internally discovered assets, the company has increasingly pursued external innovation through licensing agreements with biotechnology partners. Hansoh Pharma has become one of those strategic collaborators, providing GSK access to promising oncology candidates originating from China.
This approach reflects a wider industry trend in which multinational pharmaceutical companies are looking beyond traditional innovation hubs to secure differentiated assets capable of addressing unmet medical needs.
While global competition in the ADC market continues to intensify, positive late-stage clinical data are becoming an increasingly important differentiator as companies seek therapies that can demonstrate meaningful survival benefits rather than incremental improvements.
Healthcare Insight Analysis
The significance of this announcement extends beyond a single positive clinical trial.
Over the past several years, antibody-drug conjugates have evolved into one of the fastest-growing areas of oncology research, attracting substantial investment, licensing activity and strategic partnerships across the pharmaceutical industry. Success is no longer measured solely by scientific novelty but by the ability to generate robust late-stage clinical evidence that supports regulatory approval and commercial adoption.
For GSK, the Phase III outcome provides early validation of its strategy to complement internal research with externally sourced innovation. It also illustrates how licensing agreements with Chinese biotechnology companies are becoming an increasingly important avenue for global pharmaceutical companies seeking to strengthen their oncology pipelines.
At the same time, the results reinforce the growing importance of B7-H3 as a therapeutic target. As more companies advance B7-H3-directed therapies through clinical development, competition is likely to shift from target selection to demonstrating superior clinical outcomes, safety profiles and real-world value.
Market implications
If subsequent regulatory submissions and global clinical studies produce consistent results, Ris-Rez could strengthen GSK’s position within the increasingly competitive ADC landscape.
More broadly, the trial reinforces two trends shaping the future of oncology: first, the continued expansion of ADCs as a major therapeutic platform for solid tumors; and second, the rising role of cross-border licensing between multinational pharmaceutical companies and Chinese innovators in accelerating the global development of next-generation cancer therapies.
Source: https://www.biopharmadive.com/news/gsk-hansoh-china-adc-ris-rez-lung-cancer-results/824931/